Full saturation radiography study for one compound
Ended Purchase Order Awarded Last action
- Contract number
- 75N95021P00392
- Awardee
-
Invicro LLC UEI NCNZRA2WSKC5 Part of Konica Corp.
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $35,130
Award facts
- Opportunity
-
- Full Saturation Radiography Study for One Compound Pre-Solicitation · 75N95021Q00227 · Posted Jun 11, 2021
- Full Saturation Radiography Study for One Compound Solicitation · Posted Jul 12, 2021
- Contract value 100% obligated
- $35,130.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541380 Testing Laboratories and Services
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Great Britain, United Kingdom
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $35,130 |
About this award
This contract was awarded by the Department of Health and Human Services' National Institutes of Health National Center for Advancing Translational Sciences to Invicro LLC, a global contract research organization, to perform a full saturation radiography study for one compound. The contract is a firm-fixed-price purchase order with a potential value of $35,130.00. It does not have a set-aside designation. Invicro, which is owned by the Konica Corporation, has previously provided services such as full saturation radiography studies, in situ hybridization services, and imaging coordination and management to federal agencies including the NIH and the National Institute on Drug Abuse. This study aims to determine the occupancy of a known dopamine D3 receptor selective antagonist in D3 receptor-rich regions of the rat brain, as well as its selectivity over the D2 receptor, to support the development of novel D3 receptor antagonists for the treatment of psychostimulant addiction and relapse.
Quick answers
Who was awarded contract 75N95021P00392?
75N95021P00392 was awarded to Invicro LLC by National Institute on Drug Abuse (National Institutes of Health) on August 6, 2021.
How much is contract 75N95021P00392 worth?
The government has obligated $35,130 on 75N95021P00392.
Which agency awarded contract 75N95021P00392?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95021P00392, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Was contract 75N95021P00392 competed?
The extent of competition for 75N95021P00392 was competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award